Immunotherapy approaches in the treatment of malignant brain tumors

1057PDFINAL RESULTS FROM A CANCER RESEARCH UK FIRST IN MAN PHASE I TRIAL OF IMA950 (A NOVEL MULTI PEPTIDE VACCINE) PLUS GM-CSF IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

(2017) S. Halford et al.   ANNALS OF ONCOLOGY

Ipilimumab and Bevacizumab in Glioblastoma

(2016) T. Carter et al.   CLINICAL ONCOLOGY

Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model

(2016) Mitsuto Hanihara et al.   JOURNAL OF NEUROSURGERY

Glioblastoma vaccine therapy disappointment in Phase III trial

(2016) Hemi Malkki   Nature Reviews Neurology

Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma

(2015) Elias J. Sayour et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hostile Takeover: Glioma Stem Cells Recruit TAMs to Support Tumor Progression

(2015) Yu Shi et al.   Cell Stem Cell

The Evolution of T-cell Therapies for Solid Malignancies

(2015) K. Fousek et al.   CLINICAL CANCER RESEARCH

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Exploring the antitumor effect of virus in malignant glioma

(2015)   DRUGS OF THE FUTURE

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules

(2015) Aleksanteri Aspelund et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Heat shock protein vaccines against glioblastoma: from bench to bedside

(2015) Leonel Ampie et al.   JOURNAL OF NEURO-ONCOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy

(2015) Ichiyo Shibahara et al.   Molecular Cancer

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

(2015) Duane A. Mitchell et al.   NATURE

Structural and functional features of central nervous system lymphatic vessels

(2015) Antoine Louveau et al.   NATURE

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

(2015) J. Schuster et al.   NEURO-ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites

(2015) Powell Perng et al.   Frontiers in Oncology

Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro

(2014) Christian Pieper et al.   BRAIN RESEARCH

Oncolytic polio virotherapy of cancer

(2014) Michael C. Brown et al.   CANCER

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

(2014) S. K. Nair et al.   CLINICAL CANCER RESEARCH

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival

(2014) Andrea Gras Navarro et al.   JOURNAL OF IMMUNOLOGY

Reliability of HSP70 (HSPA) expression as a prognostic marker in glioma

(2014) Glenda Maria Beaman et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

(2014) James M Markert et al.   MOLECULAR THERAPY

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ONCOLYTIC DELTA-24-RGD (DNX-2401) WITH BIOLOGICAL ENDPOINTS: IMPLICATIONS FOR VIRO- IMMUNOTHERAPY

(2014) F. F. Lang et al.   NEURO-ONCOLOGY

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma

(2014) Hongsheng Miao et al.   PLoS One

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

(2014) Zineb Belcaid et al.   PLoS One

DCVax®-L—Developed by Northwest Biotherapeutics

(2014) Stavros Polyzoidis et al.   Human Vaccines & Immunotherapeutics

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy

(2014) Jianfang Ning et al.   Frontiers in Microbiology

Establishment of Tumor-Associated Immunity Requires Interaction of Heat Shock Proteins with CD91

(2014) Y. J. Zhou et al.   Cancer Immunology Research

Cytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme

(2014) Andrea Schuessler et al.   Frontiers in Oncology

Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

(2013) Xiao-Jun Xu et al.   CANCER LETTERS

Drainage of Cells and Soluble Antigen from the CNS to Regional Lymph Nodes

(2013) Jon D. Laman et al.   Journal of Neuroimmune Pharmacology

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination

(2013) Erik HJG Aarntzen et al.   OncoImmunology

Basis of CTLA-4 function in regulatory and conventional CD4+ T cells

(2012) X. Tai et al.   BLOOD

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

(2012) Surasak Phuphanich et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein

(2012) C. A. Crane et al.   CLINICAL CANCER RESEARCH

MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

(2012) A. Juszczak et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Consensus on the role of human cytomegalovirus in glioblastoma

(2012) K. Dziurzynski et al.   NEURO-ONCOLOGY

Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I

(2011) T. R. Sippel et al.   CLINICAL CANCER RESEARCH

Oncolytic poliovirus against malignant glioma

(2011) Christian Goetz et al.   Future Virology

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heat Shock Proteins: Cell Protection through Protein Triage

(2011) David Lanneau et al.   TheScientificWorldJOURNAL

Imaging of cellular therapies

(2010) M. Srinivas et al.   ADVANCED DRUG DELIVERY REVIEWS

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments

(2009) Oliver M. Grauer et al.   BRAIN PATHOLOGY

Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression

(2009) Benjamin Johnson et al.   CURRENT MOLECULAR MEDICINE

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Glioblastoma-Derived Mechanisms of Systemic Immunosuppression

(2009) Allen Waziri   NEUROSURGERY CLINICS OF NORTH AMERICA

Toward effective immunotherapy for the treatment of malignant brain tumors

(2009) Duane A. Mitchell et al.   Neurotherapeutics

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Oncolytic measles virus strains in the treatment of gliomas

(2008) Cory Allen et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Toxicology Study of Repeat Intracerebral Administration of a Measles Virus Derivative Producing Carcinoembryonic Antigen in Rhesus Macaques in Support of a Phase I/II Clinical Trial for Patients with Recurrent Gliomas

(2008) Rae Myers et al.   HUMAN GENE THERAPY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Recombinant Oncolytic Poliovirus Eliminates Glioma In Vivo Without Genetic Adaptation to a Pathogenic Phenotype

(2008) Elena Y Dobrikova et al.   MOLECULAR THERAPY

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE

Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

(2007) Duane A. Mitchell et al.   NEURO-ONCOLOGY